CompletedPhase 3NCT01321541
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CTI BioPharma
- Principal Investigator
- Simran B Singh, MS, GWCPSr. Director, Clinical Operations
- Intervention
- Pixantrone + Rituximab(drug)
- Enrollment
- 312 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2018
Study locations (30)
- Arizona Clinical Research Center, Tucson, Arizona, United States
- Arizona Oncology Associates, Tucson, Arizona, United States
- Highlands Oncology Group, Bentonville, Arkansas, United States
- Highlands Oncology Group, Fayetteville, Arkansas, United States
- Rocky Mountain Cancer Centers, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers, Boulder, Colorado, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- George Washington University Department of Medicine, Washington D.C., District of Columbia, United States
- Integrated Community Oncology Network-St. Vincent's, Jacksonville, Florida, United States
- Integrated Community Oncology Network-Southside, Jacksonville, Florida, United States
- Integrated Community Oncology Network, Orange Park, Florida, United States
- Carle Physician Group, Danville, Illinois, United States
- Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
- Crossroads Cancer Center, Effingham, Illinois, United States
- Carle Foundation Physician Services, Mattoon, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01321541 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha